-
公开(公告)号：US20240252488A1
公开(公告)日：2024-08-01
申请号：US18246773
申请日：2021-09-27
Inventor： Jong Yeon HWANG , Hyunjun KIM , Hyowon MUN , Hyun Jin KIM , Jae Du HA , Sung Yun CHO , Chang Soo YUN , Pilho KIM , Jisoo LEE , Joon Gyo OH
IPC: A61K31/497 , A61K31/4439 , A61K31/444 , A61K47/54 , A61K47/55 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
CPC classification number: A61K31/497 , A61K31/4439 , A61K31/444 , A61K47/545 , A61K47/55 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
Abstract: The present disclosure provides a compound of a specific chemical structure binding to MLKL or having an MLKL inhibiting or degrading activity, or pharmaceutically acceptable salts thereof. The present disclosure provides a composition comprising such compound or pharmaceutically acceptable salts thereof. The present disclosure provides the pharmaceutical use of the compound according to the present invention, salts thereof, and a composition comprising same for treating or preventing MLKL-related diseases. The present disclosure also provides a method for treating or preventing MLKL-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present invention, salts thereof, or a composition comprising same.
-
2.发明公开公开(公告)号：US20240018123A1
公开(公告)日：2024-01-18
申请号：US18017997
申请日：2021-07-28
Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY , UBIX THERAPEUTICS, INC.
Inventor： Jong Yeon HWANG , Jae Du HA , Hyun Jin KIM , Sung Yun CHO , Pilho KIM , Chong Ock LEE , Jeong Hoon KIM , Byoung Chul PARK , Sung Goo PARK , Sunhong KIM , Yuri CHOI , Yaejin WOO , Song Hee LEE , Je Ho RYU , Jungmin AHN , Ji Youn PARK , Onnuri BAE , Hanwool KIM
IPC: C07D401/14 , C07D295/155 , C07D211/26
CPC classification number: C07D401/14 , C07D211/26 , C07D295/155
Abstract: The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of AR-related diseases. The present disclosure also provides a method for treating or preventing AR-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising same.
-
公开(公告)号：US20250161271A1
公开(公告)日：2025-05-22
申请号：US18838591
申请日：2023-02-15
Inventor： Donggeon KIM , Yeri LEE , Sang Kyun LIM , Young Sook SHIN , Soo Bong HAN , Chang Soo YUN , Hyuk LEE , Hyun Jin KIM , Joo Youn LEE , Si Kwang SEONG , Taeyoung YOON , Youngrae LEE
IPC: A61K31/407 , A61K31/381 , A61K31/397 , A61K31/4155 , A61K31/4436 , A61K31/4535 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P35/00
Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising a novel compound that inhibits the activity of prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compound of the present invention inhibited the activity of prostaglandin E2 receptor and inhibited tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that when administered in combination with other anticancer agents such as a chemotherapeutic agent and/or an immune checkpoint inhibitor, a synergistic effect was exhibited in anticancer activity. Therefore, a pharmaceutical composition for treating cancer, comprising the novel compound and an anticancer agent as active ingredients may be effectively used for the prevention and treatment of cancer.
-
公开(公告)号：US20220105188A1
公开(公告)日：2022-04-07
申请号：US17429321
申请日：2020-02-07
Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventor： Jong Yeon HWANG , Jae Du HA , Sung Yun CHO , Pilho KIM , Chang Soo YUN , Hyun Jin KIM , Sung Goo PARK , Byoung Chul PARK , Jeong Hoon KIM , Sunhong KIM
Abstract: The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., EED or PRC2, utilizing cereblon E3 ubiquitin ligase, VHL E3 ubiquitin ligase, MDM2 E3 ubiquitin ligase, and cIAP E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.
-
Patent Agency Ranking
5.发明公开公开(公告)号：US20240285778A1
公开(公告)日：2024-08-29
申请号：US18573904
申请日：2022-06-24
Inventor： Pil Ho KIM , Sung Yun CHO , Jae Du HA , Chi Hoon PARK , Jong Yeon HWANG , Hyun Jin KIM , Song Hee LEE , Ye Seul LIM , Han Wool KIM , Sun Mi YOO , Beom Seon SUH , Ji Youn PARK , Je Ho RYU , Jung Min AHN , Hee Jung MOON , Ho Hyun LEE
CPC classification number: A61K47/55 , A61K47/545 , A61K47/60
Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
-
公开(公告)号：US20220386607A1
公开(公告)日：2022-12-08
申请号：US17770681
申请日：2020-10-21
Inventor： Young Kwan KO , Eun Ae KIM , Ill Young LEE , Hee Nam LIM , Jung Sub CHOI , Jee Hee SUH , Nack Jeong KIM , Dong Wan KOO , Hyun Jin KIM , Gyu Hwan YON , Jae Deok KIM , Seungae OH , So-Young LEE , Chan Yong PARK , Yun Kyoung HWANG , Byung Hoon AHN , Ah Reum KIM , Hye Ji HAN , Sungjun PARK , Junhyuk CHOI , Jisoo LIM , Mi Sook HONG
IPC: A01N43/40 , A01N43/713 , A01P13/00
Abstract: The present invention relates to a novel nicotinamide compound, a method for preparing the same, and a herbicide comprising the compound. The compound of the present invention is useful as a herbicide for foliar treatment or soil treatment because it has high safety for wheat or corn and has excellent herbicidal activity against grassy weeds, sedge weeds or broadleaf weeds.
-
公开(公告)号：US20250082762A1
公开(公告)日：2025-03-13
申请号：US18949466
申请日：2024-11-15
Inventor： Pil Ho KIM , Sung Yun CHO , Jae Du HA , Chi Hoon PARK , Jong Yeon HWANG , Hyun Jin KIM , Song Hee LEE , Ye Seul LIM , Han Wool KIM , Sun Mi YOO , Beom Seon SUH , Ji Youn PARK , Je Ho RYU , Jung Min AHN , Hee Jung MOON , Ho Hyun LEE
Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
-
公开(公告)号：US20250073341A1
公开(公告)日：2025-03-06
申请号：US18949437
申请日：2024-11-15
Inventor： Pil Ho KIM , Sung Yun CHO , Jae Du HA , Chi Hoon PARK , Jong Yeon HWANG , Hyun Jin KIM , Song Hee LEE , Ye Seul LIM , Han Wool KIM , Sun Mi YOO , Beom Seon SUH , Ji Youn PARK , Je Ho RYU , Jung Min AHN , Hee Jung MOON , Ho Hyun LEE
Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
-
9.发明公开公开(公告)号：US20230365582A1
公开(公告)日：2023-11-16
申请号：US18042352
申请日：2021-08-20
Inventor： Young Sook SHIN , Sang Kyun LIM , Yeri LEE , Donggeon KIM , Soo Bong HAN , Chang Soo YUN , Hyun Jin KIM , Joo Youn LEE , Hyuk LEE , Sikwang SEONG
IPC: C07D495/04 , C07D333/24 , C07D333/38 , C07D409/10 , C07D409/06
CPC classification number: C07D495/04 , C07D333/24 , C07D333/38 , C07D409/10 , C07D409/06
Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E2 receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.027 seconds)
